Canine Influenza Vaccine Market
The future of the global canine influenza vaccine market looks promising with opportunities in the vaccination clinic, pet hospital and others markets. The global canine influenza vaccine market is expected to reach an estimated $2.3 billion by 2035 from $1.6 billion in 2027 with a CAGR of 5.1% from 2027 to 2035. The major drivers for this market are increasing awareness of canine influenza, rising pet ownership, and growing adoption of preventive healthcare.
- Lucintel forecasts that, within the type category, H3N2 vaccine is expected to witness higher growth over the forecast period due to expansion to more locations and higher rates of h3n2.
- Within the application category, pet hospital is expected to witness the higher growth over the forecast period due to increasing pet ownership leading to more visits to pet hospitals for vaccinations.
- In terms of regions, APAC is expected to witness the highest growth over the forecast period due to rising pet ownership and veterinary spending in the Asia Pacific region.
Emerging Trends in Canine Influenza Vaccine Market
From 2025 through 2027, the canine influenza vaccine will transition from a largely reactive veterinary product to a more preventative market. There are multiple factors that drive demand including increased pet ownership, consolidation of veterinary clinics, enhanced surveillance, and boarding-related transmission of the disease. Based on Lucintel's market perspective, the competition for veterinary revenue will drive manufacturers toward differentiated formulations, stronger distribution, and evidence-based purchasing.
- Preventive Vaccination: Canine influenza vaccination is increasingly recommended by clinics prior to boarding, day care, travel, and group training. An annual booster of the two-dose primary series of Nobivac(R) Canine Flu H3N2/H3N8 is recommended. Within the next three to five years, prevention will create a demand beyond the control of outbreaks.
- Evidence-Based Adoption: Documented regional exposure, laboratory surveillance, and risk-based protocols will shift veterinary decision-making. During 2025, however, the AVMA continued to endorse the discussion of vaccination with owners within their guidance pertaining to respiratory diseases. With better epidemiological evidence, there will be less uneven adoption of vaccines and a justified price increase.
- Combination Formulations: Manufacturers tend to favor formulations that combine protection against canine influenza with established core or lifestyle vaccines, as demonstrated by the product offerings from Zoetis and Merck Animal Health. Within the next five years, combination strategies will enhance clinic economics and lower missed-dose rates.
- Cold Chain Digitization: Vaccine distributors and veterinary sectors are adding digital inventory controls, temperature monitoring, and reminder systems. In 2023, U.S. veterinary practices recorded 135 million companion animal visits, making this a large opportunity for workflow digitization. Better vaccine handling and reminder systems will improve the efficacy of vaccine potency as well as help owners complete recommended vaccination schedules.
- Regional Preparedness: Increased preparedness for outbreaks has LED regional vaccination clinics to more actively develop stock plans beyond relying on emergency orders. More flexible manufacturing and transportation systems has allowed veterinary supply companies to develop a stable recurring clientele in high-volume urban areas.
The stabilization of outbreak preparedness will drive the veterinary supply market towards routine risk management. Additionally, realizing the vaccination pulse market will be driven by veterinary supply companies with the ability to maximize surveillance reliability, convenience of combination products, and veterinary data systems. The preference will remain price, but compliance and prevention will drive purchase decisions.
Recent Developments in the Canine Influenza Vaccine Market
The canine influenza vaccine market is expected to be more active between the years 2025 and 2027, due to growing outbreaks, demand for boarding services, and increasing veterinarian awareness of the need for preventive measures. According to Lucintel, growth will be more incremental rather than substantial. Vendors are improving strain coverage, distribution, and clinical messaging, while vaccine purchasing decisions are becoming increasingly more influenced by surveillance.
- Bivalent Vaccine Positioning: Nobivac Canine Flu H3N2/H3N8 is providing support for vaccine formulation to provide protection against the emerging variants of the virus (January 2025). Two strain vaccines can provide protection to the veterinary clinic against multiple viral strains and make vaccinations more economical.
- Veterinary Channel Expansion: Both Zoetis and Merck Animal Health are expanding their availability for companion animals to veterinary clinics through their distribution networks and more convenient ordering (March 2025). Better availability will decrease the number of unvaccinated animals among boarding and daycare patrons.
- Outbreak-led Demand: Canine influenza reports are concentrated in certain geographic regions, but shelters and boarding care facilities are now requiring vaccination of their dogs (June 2025). These requirements have changed the nature of outbreak demand from scattered to sustained and more predictable.
- Surveillance-driven Formulation: The USDA and veterinary laboratories are actively monitoring H3N2 and H3N8, and are providing the justification for vaccine recommendations (September 2025). Improving surveillance can motivate vendors to make focused and rapid updates to existing product offerings.
- Preventive-care Bundling: Many clinics now encourage vaccination for canine influenza as a routine part of wellness exams and also as a part of travel Russell vaccinations (February 2026). These types of bundling initiatives lead to greater patient compliance and offer clinics more predictable recurring revenue.
Reluctance to widely vaccinate against COVID-19 means that targeted vaccination will hire more of the commercial momentum. Response occurs fastest from breeders, boarding facilities, shelters, participants at dog shows, and people with multiple dogs. Companies that simplify the two-dose initiation and provide clinics with education to combat large dog flu outbreaks should gain a greater market share. Price continues to be a major barrier, particularly if dog owners do not believe canine influenza is a vital vaccination. Regional dog kennel mandates and increased pet benefits offered by insurance or employers should also help reinforce the market. More consistent market revenue is likely as preventive measures are done more frequently, and this will likely be the case until 2027. Market growth will occur more for companies that increase their veterinary trust and less for new dogs in the market, or aggressive pricing.
Strategic Growth Opportunities in the Canine Influenza Vaccine Market
The market for canine influenza vaccines is gaining traction due to factors such as pet boarding, traveling, and daycare. Risk-based vaccination protocols will be adopted by veterinarians in the upcoming years from 2024 to 2026. During this period, vaccine manufacturers will focus on developing innovative vaccines. Lucintel predicts that there will be high demand for vaccines in future due to factors such as increasing investments in disease surveillance and prevention, increase in the number of pet shelters and clinics, and higher pet ownership.
- New Opportunities: Vaccination is now not restricted to protection of the animal and is used for boarding, grooming, transporting, and sheltering of pets. In January 2025, protection against the two canine influenza strains became a mandatory requirement for several boarding facilities in the USA. It is likely that in the next three to five years, the push for vaccinations will be from the institutions rather than voters.
- High Value Products: By developing longer acting vaccines, vendors can increase the price of their products. Simplifying the vaccination schedule and developing combination products that provide protection against more than one disease can reduce the number of visits to the clinic and increase the price of the product. In June 2025, canine influenza products with the USDA license continued to focus on the two major canine influenza strains H3N8 and H3N2. High value protection is likely to increase both pet owners' and veterinarians' satisfaction.
- Geographical Growth: There is potential for vendors to enter the Asian Pacific, Latin American, and African markets where urban pet ownership is growing but lacks and lags preventive care. In February 2025, the companion animal market in China grew to include over 120 million dogs and 120 million cats combined. Growing local partnerships and regulatory policies has the potential to increase market access.
- Sustainable Materials: Vaccine companies can stand out by implementing more efficient vaccine packaging and increased supply clinic recyclability. In April 2025, the World Health Organization stated that temperature-controlled pharmaceuticals are typically in the range of 2-8 degrees Celsius. With increased focus on the environment, procurement concerns will become more energy and packaging-related.
- Customized Solutions: As veterinary services grow, so will the need for protocols specific to shelter densities, travel patterns, outbreak histories, and the age of the animals. In September 2025, a U.S. shelter network that houses over 500 dogs implemented site-specific controls for respiratory diseases. Data-based protocols will help achieve higher-value contracts and enhance the compliance of vaccination schedules.
Products that align with the clinic workflow and offer practical protection will be the most successful. These products will also help clinics with clear communication for the risks associated with the product. The greatest opportunity for growth will not come from broad-based vaccine programs but controlled vaccine programs for targeted facilities, travel, and population densities. There is potential for companies to maintain consistent revenue streams along fragmented veterinary channels if they have both regulatory and operational competencies.
Canine Influenza Vaccine Market Drivers and Challenges
Factors influencing canine influenza vaccine market growth include the growing demand for pets, the expanding capacity of veterinary services, upgraded vaccines, and the increasing knowledge aimed at the prevention of infectious diseases. The impacts of economic conditions relate to the affordability of treatments, and with respect to regulatory conditions, to the approval and distribution of the products. Lucintel identifies demand volatility, limited surveillance, and uneven vaccination practices as key challenges of new market development.
The factors responsible for driving this market include:
- Rising Disease Awareness: More pet owners and veterinarians recognize canine influenza as a preventable infectious disease that poses a significant respiratory risk, especially as the animals are housed in a boarding kennel, or in a shelter, daycare center or show. More vaccinations are advocated as the educational campaigns and innovation in the diagnostics of canine influenza suggest that potential clients are more ready to discuss the need for vaccination. Although 2025 was a significant year for veterinary conferences and for the issuance of updated clinical guidance, the regional adoption of prevention of respiratory diseases continued to lag. It is anticipated that in the next three to five years there will be greater awareness sub-optimal preventive medicine, and will lead to wider vaccination of at-risk dogs and increased demand for booster vaccinations.
- Growth in Pet Healthcare Spending: Owners are more willing to pay for services related to preventative veterinary care including diagnostics and vaccinations. Because of this, vaccination becomes an economic valve for treatment and loss of work, and potentially, more severe consequences. The American Pet Products Association reported that in 2024, the pet service industry expenditures in the United States reached $150.6 billion. In the next three to five years, premium and insurance enhancements will encourage the use of more vaccinations.
- Advances in Vaccine Technology: Adjuvant selection and combination formulations, as well as the selection of antigens and improvement in stability of vaccines during storage are all areas that vaccine manufacturers have been targeting to develop more simpler and efficient platforms for vaccinations. Product innovations in vaccines can reduce the burden of multiple visits to the clinic on pet shelters, breeders and owners of multiple dogs. In 2025, canine influenza vaccines continued to be offered mainly as two-dose initial series products, showing the emphasis on compliance with complete dosage vaccination schedules. During the next three to five years, the introduction of longer acting formulations could strengthen compliance and improve utilization.
- Expansion of Veterinary Services Infrastructure: An increase in Veterinary hospitals, mobile clinics, diagnostic laboratories, and even pet care networks can increase the opportunities to identify unvaccinated pets and to determine the need for vaccinations. An increase in veterinary facilities in the United States in 2025, to more than 32,000, shows improvement in the available infrastructure for the delivery of preventative services. During the next three to five years, particularly in developing countries, the improved infrastructure will lead to an increase in vaccinations.
- Institutional and Regulatory Support: Shelters and kennels, plus personnel from the public health sector and veterinary associations, are advocating for increased vaccination in kenneled dogs. While canine influenza is considered to be a risk-based vaccination, the establishment of policies and guidelines can drive the demand for vaccination during an outbreak. In 2025, veterinary associations and other organizations continued to advise risk assessment vaccinations for boarding, travel, exhibition and day care. Over the next three to five years, standardized codification of guidelines and improvements in the regulatory evaluation of products will strengthen the market's trust and confidence in the vaccines offered.
The challenges facing this market include:
- Inconsistent Vaccination Advice: Because exposure to canine influenza changes based on geography, lifestyle, and nearby outbreaks, vaccination is not recommended for all dogs. As a result, most owners choose to vaccinate their dogs only when their vet recommends it due to exposure risk. Until then, vaccine demand is based on outbreak news, and, as a result, baseline coverage is inadequate. In 2025, most vaccination decisions were made based on exposure to boarding, daycare, shelters, or shows. Over the next three to five years, canine influenza will likely continue have unpredictable sales in low-risk areas due to inconsistent recommendations.
- Insufficient Disease Tracking: There are many reasons for insufficient diagnosis and tracking of canine influenza, including fragmented reporting, inconsistent veterinary diagnosis, and variability in veterinary systems. Undiagnosed cases can lead to a false sense of normalcy and create bursts in demand that do not result in sustained buying. During 2025, veterinary diagnostic laboratories continued performing molecular tests to differentiate influenza among other respiratory pathogens, but surveillance remained unreliable. Over the next three to five years, insufficient data will make forecasting more challenging and create more hesitancy to fund additional vaccine production.
- Affordability and Distribution Constraints: Some factors that may deter limited income owners from vaccinating their pets include the cost of vaccines, veterinary consultations, cold-chain logistics, and the multiple doses required initially. Rural areas and emerging economies may struggle to vaccinate their pets due to an insufficient number of clinics, adequate personnel, and working refrigerators. The U.S. Bureau of Labor Statistics indicated in their April 2025 report that prices for veterinary services increased by 3.8% in the last year. In the next 3 to 5 years, it is expected that issues related to affordability will restrict vaccine adoption unless manufacturers focus on low-cost vaccines, efficient vaccine distribution, and preventive care programs.
The canine influenza vaccine market will grow with a focus on preventive care as the factors that influence the market grow, like the availability of funds for pet healthcare, education on diseases, improvement in the veterinary infrastructure, and new innovations in vaccines. Fluctuations in discretionary recommendations, surveillance, rising veterinary costs, uneven regional distribution, and the lack of coordinated regulation will create an environment where some segments of the market grow at the expense of others. Offering vaccines that are both affordable and convenient will help create new markets in the prevention of infectious diseases. Overall uneven market growth will be most influenced by existing healthcare infrastructure and the economic benefits of prevention and vaccination.
List of Canine Influenza Vaccine Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies canine influenza vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the canine influenza vaccine market companies profiled in this report include-
- Bharat Biotech
- GSK
- Novartis
- Merck Animal Health
- Roche
- Zoetis
- CSL Limited
Canine Influenza Vaccine Market by Segment
The study includes a forecast for the global canine influenza vaccine market by type, application, and region.
Canine Influenza Vaccine Market by Type [Value ($B) from 2019 to 2035]:
- H3N2 Vaccine
- H3N8 Vaccine
Canine Influenza Vaccine Market by Application [Value ($B) from 2019 to 2035]:
- Vaccination Clinic
- Pet Hospital
- Others
Canine Influenza Vaccine Market by Region [Value ($B) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Canine Influenza Vaccine Market
Except for large-scale consumer launches, the canine influenza vaccine market is still influenced by regulatory approvals, veterinary biologics production, and multinational portfolio decisions. For the time period ranging between 2025 to 2027, suppliers will allocate resources on H3N2 and H3N8 licensed strains, and governmental agencies will continue to monitor the risks associated with cross-border animal diseases. According to Lucintel's new assessment of the market, market development will be dictated by product availability and regulatory progress.
- United States: USDA-licensed Nobivac Canine 1-DAPPvL2+Cv and Vanguard CIV products will still support dual-strain and remain the only, approved products for canine influenza in the US. In January 2025, the USDA APHIS still controlled the veterinary biologics rule requiring an efficacy and safety report for canine influenza products. The regulatory structure will maintain the standards for licensing and continue to sustain the market over the next three to five years.
- China: In 2025, the Ministry of Agriculture and Rural Affairs continued to implement veterinary biologics regulations as well as import vet control, while companion animal vaccine manufacturers continued to expand their portfolios. In June 2025, veterinary biologics regulations in China continued to require prior approval of the batch. This will continue to support the market for approved imported vaccines and more registered domestic vaccines.
- Germany: Germany remains a key manufacturing and distribution base for Boehringer Ingelheim's animal health products for canine respiratory disease. In March 2025, the company reported sales of EUR 5 billion Euro for 2024 for animal health globally. Investing in regulated production and the European supply chain will continue to influence the supply and concentration of suppliers.
- India: The Department of Animal Husbandry and Dairying continued the implementation of the National Animal Disease Control Programmed in 2025. This program is mainly for the control of livestock diseases. In February of 2025, the program aimed at vaccinating 100 percent of the cattle and buffalo populations. This helps develop the veterinary infrastructure to help deliver other companion animal biologics.
- Japan: In 2025, the MAFF continued requiring approvals for veterinary products imported into the country, while domestic distributors continued to be the sole suppliers of imported canine vaccines. April 2025, sovereign veterinary drug approval continued to be governed by the Pharmaceutical and Medical Device Act. This helps maintain registration and import compliance for suppliers of canine influenza vaccines.
Features of the Global Canine Influenza Vaccine Market
- Market Size Estimates: canine influenza vaccine market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: canine influenza vaccine market size by type, application, and region in terms of value ($B).
- Regional Analysis: canine influenza vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the canine influenza vaccine market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the canine influenza vaccine market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
This report answers following 11 key questions:
- Q.1. What are some of the most promising, high-growth opportunities for the canine influenza vaccine market by type (H3N2 vaccine and H3N8 vaccine), application (vaccination clinic, pet hospital, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
- Q.2. Which segments will grow at a faster pace and why?
- Q.3. Which region will grow at a faster pace and why?
- Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
- Q.5. What are the business risks and competitive threats in this market?
- Q.6. What are the emerging trends in this market and the reasons behind them?
- Q.7. What are some of the changing demands of customers in the market?
- Q.8. What are the new developments in the market? Which companies are leading these developments?
- Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
- Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
- Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?